JPM22
Most Read
STAT Plus: FDA removes clinical hold on cancer studies of Allogene off-the-shelf CAR-T treatment
STAT Plus: Pfizer to pay Beam $300 million in gene-editing deal, amping up its mRNA ambitions
STAT Plus: Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research
STAT Plus: A preview of the burning biotech and health tech questions at JPM 2022
Covid-19 is no longer the biggest issue facing hospitals. Staffing is
STAT Plus: A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies
